Dose‐ranging antiemetic evaluation of the serotonin antagonist rg 12915 in patients receiving anticancer chemotherapy Academic Article Article uri icon

Overview

MeSH Major

  • Amyotrophic Lateral Sclerosis
  • Biomarkers
  • Muscle Weakness
  • Nerve Growth Factors
  • Neuropeptides

abstract

  • RG 12915 can be administered safely at the dose levels explored. Single intravenous doses of RG 12915 prevented or lessened emesis caused by chemotherapy, including cisplatin given at doses of greater than or equal to 100 mg/m2. RG 12915 warrants further testing. Of the doses tested, the 2.0 mg/kg dose is the most appropriate for further exploration.

publication date

  • January 1993

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19931101)72:9<2695::AID-CNCR2820720928>3.0.CO;2-S

PubMed ID

  • 8402492

Additional Document Info

start page

  • 2695

end page

  • 9

volume

  • 72

number

  • 9